Clinical Trials Browser

Eyelid Squamous Cell Carcinoma

Locally Advanced Cervical Adenocarcinoma

Uterine Cervical Neoplasms, Vaginal Neoplasms

Lung Neoplasms

Oropharyngeal Neoplasms

Nasopharyngeal Neoplasms

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Squamous Cell Carcinoma of Head and Neck

Pancreatic Intraductal Neoplasms

Nasopharyngeal Neoplasms

Nasopharyngeal Neoplasms

Stage II Prostate Adenocarcinoma AJCC v7

Nasopharyngeal Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Precancerous Conditions, Papillomavirus Infections

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

Uterine Cervical Neoplasms

Nasopharyngeal Cancinoma (NPC)

Astrocytoma, Lymphoma, Follicular

Astrocytoma, Brain Neoplasms, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Pancreatic Adenocarcinoma

Nasopharyngeal Carcinoma

Prostatic Neoplasms

Nasopharyngeal Carcinoma

Uterine Cervical Neoplasms

Nasopharyngeal Neoplasms

Prostatic Neoplasms

Brain Neoplasms, Cognitive Dysfunction

Mesothelioma, Malignant, Mesothelioma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Esophageal Squamous Cell Carcinoma

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Prostatic Neoplasms

Clinical Trials

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

PTCA199-11

DIAMOND

PEACE 7

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

GEMSTONE

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

OART

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

CONTINUUM

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Radiation Therapy in Treating Patients With Stage II Prostate Cancer